Loading…
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease; and DMX-200, a small molecule inhibitor of the chemokine receptor 2 that is in a pivotal Phase 3 study for the treatment of focal segmental glomerulosclerosis (FSGS) kidney disease. It has collaboration and license agreement with GlaxoSmithKline to develop and commercialize Galafold; and Dimerix Limited for the commercialization of DMX-200 for the treatment of FSGS and other indications. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey. As of April 27, 2026, Amicus Therapeutics, Inc. operates as a subsidiary of BioMarin Pharmaceutical Inc.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $634M | $54M | $-27M | $30M | -9.9% | 20.0% | -51.7% |
| 2024 | $528M | $29M | $-56M | $-37M | -28.9% | 32.3% | -63.0% |
| 2023 | $399M | $-92M | $-152M | $-77M | -94.6% | 21.3% | -35.9% |
| 2022 | $329M | $-200M | $-237M | $-170M | -192.3% | - | - |
| 2021 | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 329.23 | 399.36 | 528.29 | 634.21 |
| Operating Revenue | - | 329.23 | 399.36 | 528.29 | 634.21 |
| Cost Of Revenue | - | 38.60 | 37.33 | 52.94 | 72.93 |
| Gross Profit | - | 290.63 | 362.03 | 475.35 | 561.28 |
| Operating Expense | - | 495.06 | 435.52 | 441.29 | 526.79 |
| Research And Development | - | 276.68 | 152.38 | 109.36 | 135.84 |
| Selling General And Administration | - | 213.04 | 275.27 | 323.38 | 383.49 |
| Total Expenses | - | 533.66 | 472.85 | 494.23 | 599.72 |
| Operating Income | - | -204.43 | -73.49 | 34.06 | 34.49 |
| Total Operating Income As Reported | - | -212.12 | -77.21 | 24.88 | 32.79 |
| EBITDA | - | -199.58 | -92.08 | 29.39 | 53.81 |
| Normalized EBITDA | - | -191.88 | -74.43 | 38.58 | 55.51 |
| EBIT | - | -204.92 | -99.95 | 20.84 | 46.35 |
| Interest Income | - | 3.02 | 7.08 | 5.41 | 3.32 |
| Interest Expense | - | 37.12 | 50.15 | 49.60 | 46.16 |
| Net Interest Income | - | -34.10 | -43.07 | -44.19 | -42.84 |
| Other Non Operating Income Expenses | - | 4.18 | -15.89 | -9.44 | 10.24 |
| Other Income Expense | - | -3.52 | -33.54 | -18.63 | 8.54 |
| Interest Income Non Operating | - | 3.02 | 7.08 | 5.41 | 3.32 |
| Interest Expense Non Operating | - | 37.12 | 50.15 | 49.60 | 46.16 |
| Net Non Operating Interest Income Expense | - | -34.10 | -43.07 | -44.19 | -42.84 |
| Pretax Income | - | -242.04 | -150.10 | -28.76 | 0.19 |
| Tax Provision | - | -5.47 | 1.48 | 27.35 | 27.30 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | -0.15 | -3.71 | -1.93 | -0.36 |
| Net Income Continuous Operations | - | -236.57 | -151.58 | -56.11 | -27.11 |
| Net Income From Continuing And Discontinued Operation | - | -236.57 | -151.58 | -56.11 | -27.11 |
| Net Income From Continuing Operation Net Minority Interest | - | -236.57 | -151.58 | -56.11 | -27.11 |
| Net Income | - | -236.57 | -151.58 | -56.11 | -27.11 |
| Net Income Common Stockholders | - | -236.57 | -151.58 | -56.11 | -27.11 |
| Net Income Including Noncontrolling Interests | - | -236.57 | -151.58 | -56.11 | -27.11 |
| Normalized Income | - | -229.03 | -137.64 | -48.85 | -25.77 |
| Diluted NI Availto Com Stockholders | - | -236.57 | -151.58 | -56.11 | -27.11 |
| Basic Average Shares | 271.42 | 289.06 | 295.16 | 304.38 | - |
| Diluted Average Shares | 271.42 | 289.06 | 295.16 | 304.38 | - |
| Reconciled Depreciation | - | 5.34 | 7.87 | 8.55 | 7.46 |
| Reconciled Cost Of Revenue | - | 38.60 | 37.33 | 52.94 | 72.93 |
| Total Unusual Items | - | -7.69 | -17.65 | -9.19 | -1.70 |
| Total Unusual Items Excluding Goodwill | - | -7.69 | -17.65 | -9.19 | -1.70 |
| Special Income Charges | - | -7.69 | -17.65 | -9.19 | -1.70 |
| Other Special Charges | 0.26 | - | 13.93 | - | - |
| Write Off | - | 6.62 | 1.13 | 0 | 1.70 |
| Restructuring And Mergern Acquisition | - | 1.08 | 2.58 | 9.19 | 0 |
| Depreciation Amortization Depletion Income Statement | - | 5.34 | 7.87 | 8.55 | 7.46 |
| Depreciation And Amortization In Income Statement | - | 5.34 | 7.87 | 8.55 | 7.46 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Amicus Therapeutics, Inc.this co. | FOLD | $4.5B | -167.83 | 16.59 | -9.9% | 88.80 |
| CG Oncology, Inc. | CGON | $4.9B | -30.73 | 6.57 | -21.4% | -26.00 |
| Twist Bioscience Corporation | TWST | $4.6B | -59.27 | 9.73 | -16.4% | -40.36 |
| Dianthus Therapeutics, Inc. | DNTH | $4.6B | -28.33 | 9.32 | -32.9% | -25.63 |
| Celcuity Inc. | CELC | $4.5B |
| - |
| - |
| - |
| - |
| - |
| - |
| -25.47 |
| 44.85 |
| -176.1% |
| -29.21 |
| Travere Therapeutics, Inc. | TVTX | $4.3B | -168.11 | 37.40 | -22.2% | 203.89 |
| 10x Genomics, Inc. | TXG | $4.3B | -97.67 | 5.34 | -5.5% | 988.34 |
| Erasca, Inc. | ERAS | $4.1B | -33.13 | 12.69 | -38.3% | -31.96 |
| LivaNova PLC | LIVN | $4.0B | -16.70 | 3.37 | -20.2% | -34.40 |
| Peer Median | - | -31.93 | 9.53 | -21.8% | -27.60 | |